MULTI-SPIKE RELEASE FORMULATION FOR DRUG DELIVERY
FORMULIERUNG MIT MEHRFACH GEPULSTER WIRKSTOFFFREISETZUNG
PREPARATION A LIBERATION EN PLUSIEURS ETAPES DESTINEE A L'ADMINISTRATION DE MEDICAMENTS

Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Priority: 19.01.2000 US 176853 P

Date of publication of application:
16.10.2002 Bulletin 2002/42

Proprietor: Mannkind Corporation
Danbury, Connecticut 06810 (US)

Inventor: STEINER, Solomon, S.
Mount Kisco, NY 10549 (US)

Representative: Bassett, Richard Simon et al
Eric Potter Clarkson,
Park View House,
58 The Ropewalk
Nottingham NG1 5DD (GB)

References cited:
WO-A-00/35426 WO-A-00/59479

- KIMKO H C ET AL: "PHARMACOKINETICS AND CLINICAL EFFECTIVENESS OF METHYLPHENIDATE" CLINICAL PHARMACOKINETICS,ADIES INTERNATIONAL, PARIS,FR, vol. 37, no. 6, December 1999 (1999-12), pages 457-470, XP000950000 ISSN: 0312-5963
Description

Background Of The Invention

[0001] The present invention is generally in the field of pharmaceutical formulations, and more particularly related to methods and compositions for controlling the pharmacokinetic profile of drugs, such as methylphenidate, which are used in pharmaceutical applications.


[0003] Methylphenidate (trade name RITALIN™) is used to treat hyperactivity and attention deficit disorder (ADD) in children. While it is very effective when administered orally, the effects only last for only about three to four hours. It would be desirable to have a dose form that could be administered in the morning and maintain the child throughout the school day. Typical slow release formulations are not suitable because they produce a continuous slow release, approaching a zero order kinetic release profile. Methylphenidate, however, requires a spike or "saw tooth" (i.e. multi-spike) kinetic profile to be effective in the treatment of ADD.

[0004] Methylphenidate is currently being used to treat young children who differ widely in their body weight and hence their dose requirement. A desirable formulation would allow for convenient manipulation of dose by the parent. A more accurate dosing regimen could be achieved if it was provided in a formulation that was amenable to apportionment.

[0005] Methylphenidate is currently administered in pill form. It is not administered in an aqueous solution since it is so bitter. Young children frequently have difficulty swallowing pills. It would be advantageous to provide methylphenidate in a form that is easily swallowed by children and that masks the unpleasant taste of the drug.

[0006] Methylphenidate is known to be abused by individuals who inject it intravenously to achieve a "high". A desirable formulation would be difficult to inject intravenously and hence would reduce the drug's abuse liability.


[0008] EP 0 379 147 deals with an extrudable elastic gel for use as carrier for a therapeutic agent.

[0009] It is therefore an object of the present invention to provide a composition for the oral administration of methylphenidate or other drugs that require a multi-spike release.

[0010] It is another object of the present invention to provide a composition for the oral administration of methylphenidate or other drugs in an easy to swallow, preferably pleasant tasting, dosage form.

[0011] It is a further object of the present invention to provide a composition for oral administration of methylphenidate or other drugs in a form in which the dose of the drug is conveniently manipulated, but which preferably reduces the likelihood of abuse of the drug.

Summary Of The Invention

[0012] Methylphenidate or other drugs are provided in a formulation for oral administration that releases the drug in two or more pharmacokinetic spikes, by combining different release forms in a single formulation. In a preferred embodiment for methylphenidate, the first pharmacokinetic spike is achieved by the release of taste-masked methylphenidate which is not enterically coated, while a second pharmacokinetic spike is achieved by the release of methylphenidate in a finely divided form from enterically coated pellets or microparticles formulated for rapid release following dissolution of the enteric coating (i.e., delayed release particles). A critical aspect of the formulation is the inclusion of excipients that create a burst release following the initial rapid release and uptake.

[0013] The formulation can be administered as a paste, jelly, suspension, or fast dissolving wafer. The drug can be in the form of drug particles, microencapsulated particles, or drug-polymer particles. In one embodiment, both delayed release and the unprotected methylphenidate are thoroughly mixed and suspended in an appropriate medium to form a paste or a gel. Peanut butter or alginate, flavored with raspberry and a sweetener are examples of the many suitable taste masking agents.

[0014] To manipulate the dose, the formulation can be provided, for example, as a paste packaged in a tube similar to those used to dispense toothpaste. The paste can be squeezed out of an orifice of a fixed size such that a given length of paste contains a specified dose of methylphenidate, e.g., one inch contains 5 mg of methylphenidate, two inches contain 10 mg of methylphenidate. An alternative approach is to package the paste in a hypodermic syringe-like dispenser that is calibrated for dose. Yet another alternative approach is to package the formulation as a gelatinous solid, for example, a jelly candy bar. The bar can be scored or marked in units of methylphenidate for convenient dosing. Furthermore, the potential for intravenous abuse of the methylphenidate is markedly reduced when in the form of a semi-solid suspension of particles in a fat based substrate, such as in peanut butter, or a suspension of solid particles in a semi-solid gel.

Detailed Description Of The Invention

[0015] Formulations have been developed for oral administration to release drug, particularly methylphenidate, in two or more pharmacokinetic spikes, by combining different release forms into a single formulation, where a critical aspect of the formulation is the inclusion of excipients or formulation of the drug to produce immediate release and uptake of the drug after a period of
time, typically between two and eight hours, most preferably three hours, following the initial delivery and uptake of drug.

I. The Drug Formulation and Methods of Making Them

A. Drugs to be Delivered

[0016] Although essentially any drug suitable for delivery to the gastrointestinal tract can be delivered in the formulation described herein, the preferred drug is one which is beneficially delivered in two or more pharmacokinetic spikes. The preferred drug is methylphenidate (trade name RITALIN™). This drug is available as methylphenidate hydrochloride in tablets of 5, 10 and 20 mg for oral administration. A sustained release formulation is also available. These are administered in divided dosages two or three times daily. The formulations described herein are administered to achieve the same effective dosages, but require only a single administration daily.

B. Release Formulations

[0017] The multi-release formulation consists of at least two components: drug which is taken up immediately, and is typically in the form of drug particles, drug solution or drug suspension, without any enteric or controlled release coatings or capsule, and that drug that is formulated for delayed release, typically in the form of a capsule, coating, or microparticulate formulation, which delays release and uptake of the drug for a period of hours, typically between two and eight hours, more preferably about three hours. The formulation also includes a means for rapid release of the second delayed release component.

[0018] Drug formulations are well known. These can consist of pure drug, either in solution (for immediate uptake), in dry powder form, or in suspension. For the delayed release component, the drug must be in a capsule, a coated tablet, or microparticulate formulation, where the drug is not released until the capsule, coating or microparticulate material is penetrated by hydrolytic and/or enzymatic action. A variety of enteric coatings, protein coatings or films are well known to delay release.

[0019] In a preferred embodiment, additional pharmacokinetic spikes are achieved by the release of drug methylphenidate in a finely divided form from enterically coated pellets or microspheres formulated for rapid release following dissolution of the enteric coating. Pellets or microspheres having different types and/or thicknesses of enteric coatings can be combined to yield two, three or more pharmacokinetic spikes.

[0020] In a preferred embodiment, the mixture is pelleted into small particles by any one of several methods known to those skilled in the art of pharmaceutics. The pellets are then coated with any one of a number of pH sensitive enteric coating materials, which are water-resistant, by any one of several methods known to those skilled in the art of pharmaceutics.

[0021] Rapid release means preferably consist of food or drug grade which react upon exposure to water and/or a defined pH to rapidly generate a burst of gas, for example, carbon dioxide, which “blows apart” the coating, capsule or particulate composition. Typically, these will be a food acid in dry form (such as citric acid) and a dry powder substance that in combination with water and acid will rapidly form and liberate carbon dioxide (such as baking powder).

[0022] This step can be done at the same time as the drug is formed into pellets or particles. For example, equal weights of methylphenidate, citric acid and sodium bicarbonate are thoroughly mixed with a binding agent, methylcellulose, pelleted into particles having an average diameter of 2 millimeters and placed in a fluidized bed apparatus for coating with EUDRAGIT™. The pellets will produce the second “spike release” of methylphenidate because the pellets will transit the stomach intact. When the pellets have traveled approximately one third of the length of the small intestines, the pH will have risen sufficiently to dissolve the thin water resistant pH sensitive coating. This takes approximately three to four hours. When water now comes in contact with the citric acid and sodium bicarbonate, a rapid reaction occurs, releasing carbon dioxide and dispersing the methylphenidate, which because it is rapidly dispersed in a finely divided form, will be rapidly absorbed, yielding the second “pharmacokinetic spike”.

C. Carriers

[0023] The formulation can also contain binders, taste modifying components, food colorings, and viscosity modifying agents. The drug formulation may be in the form of a suspension, capsule, tablet, paste, gel, or solid or semi-solid form such as a "candy bar”. The advantages of the suspension, paste, gel, and solid or semi-solid formulations is that they are readily divided into dosages which can be made more exact based on the age and size of the recipient, and are also more difficult to abuse since they are not injectable.

[0024] Taste modifying materials are well known. Bubble gum and fruit flavorings are commonly used for pediatric formulations. For example the drug can be dissolved or suspended in an aqueous solution containing sweeteners and/or flavoring agents, which are well known in the art. Peanut butter or alginate, flavored with raspberry and a sweetener are examples of the many mediums suitable as taste masking agents.

[0025] Binding agents may also be added if necessary or desirable. For example, the formulation can be administered orally as a paste, jelly, suspension, or fast dissolving wafer. In one embodiment, both the pelleted and the unprotected methylphenidate are thoroughly mixed and suspended in an appropriate medium to form
a paste or a gel.

[0026] In a preferred embodiment for methylphenidate, the first pharmacokinetic spike is achieved by the release of taste-masked methylphenidate which is not enterically coated, while a second pharmacokinetic spike is achieved by the release of methylphenidate in a finely divided form from enterically coated pellets or microparticles formulated for rapid release following dissolution of the enteric coating.

II. Methods of Administration and Dosage Manipulation

[0027] To manipulate the dose, the formulation can be provided, for example, as a paste packaged in a tube similar to those used to dispense toothpaste. The paste can be squeezed out of an orifice of a fixed size such that a given length of paste contains a specified dose of methylphenidate, e.g., one inch contains 5 mg of methylphenidate, two inches contain 10 mg of methylphenidate.

[0028] An alternative approach is to package the paste in a hypodermic syringe-like dispenser that is calibrated for dose. Yet another alternative approach is to package the formulation as a gelatinous solid, for example, a jelly candy bar. The bar can be scored or marked in units of methylphenidate for convenient dosing.

Claims

1. A composition for the oral administration of a drug to a patient comprising
   a first component in a form releasing a first dose of the drug immediately following ingestion of the composition; and
   a second component in a form rapidly releasing a second dose of the drug at a second time after release of the first dose,
   wherein the first and second doses provide a multi-spike pharmacokinetic profile of the drug and wherein the rapid release is achieved through the use of reagents that, upon exposure to water, generate a burst of gas reagents that immediately disperses or exposes the second dose of the drug so that it can be absorbed through the gastrointestinal tract.

2. The composition of claim 1 wherein the drug is methylphenidate.

3. The composition of claim 1 comprising taste masking materials.

4. The composition of claim 1 wherein the drug of the second component is enteric coated and rapidly released in a finely divided form following dissolution of the enteric coating.

5. The composition of claim 1 wherein the second component is in the form of pellets or microspheres comprising an acid and a dry powder, wherein the dry powder and acid, upon contact with water, will form and liberate carbon dioxide.

6. The composition of claim 5 wherein the acid is a food acid and the dry powder is baking powder.

7. The composition of claim 5 comprising a binding agent wherein the composition is in the form of a solid or semi-solid food or candy.

8. The composition of claim 1 in the form of a paste, jelly, suspension, or fast-dissolving wafer.

9. The composition of claim 1 in the form of a gelatinous solid.

10. The composition of claim 2 wherein the second dose is released after two to eight hours following release of the first dose.

11. The composition of claim 10 in the form of a paste or gel, capable of being administered using a compressible device for dispensing a measured dose of the composition.

12. The composition of claim 1 in the form of a solid or semi-solid which can be apportioned to provide the correct dosage form, and is suitable for being apportioned at the time of administration to an individual in need of treatment thereof.

13. Use of the composition of any one of claims 2, 10 or 11 in the manufacture of a medicament for the treatment of hyperactivity and/or attention deficit disorder in children.

14. A drug dosage dispenser comprising
   a composition for the oral administration of a drug to a patient comprising
   a first component in a form releasing a first dose of the drug immediately following ingestion of the composition; and
   a second component in a form rapidly releasing a second dose of the drug at a second time after release of the first dose,
   wherein the first and second doses provide a multi-spike pharmacokinetic profile of the drug and wherein the rapid release is achieved through the use of reagents that, upon exposure to water, generate a burst of gas reagents that immediately disperses or exposes the second dose of the drug so that it can be absorbed through the gastrointestinal tract.

15. The composition of claim 1 wherein the second component is in the form of pellets or microspheres comprising an acid and a dry powder, wherein the dry powder and acid, upon contact with water, will form and liberate carbon dioxide.

16. The composition of claim 5 wherein the acid is a food acid and the dry powder is baking powder.

17. The composition of claim 5 comprising a binding agent wherein the composition is in the form of a solid or semi-solid food or candy.

18. The composition of claim 1 in the form of a paste, jelly, suspension, or fast-dissolving wafer.

19. The composition of claim 1 in the form of a gelatinous solid.

20. The composition of claim 2 wherein the second dose is released after two to eight hours following release of the first dose.

21. The composition of claim 10 in the form of a paste or gel, capable of being administered using a compressible device for dispensing a measured dose of the composition.

22. The composition of claim 1 in the form of a solid or semi-solid which can be apportioned to provide the correct dosage form, and is suitable for being apportioned at the time of administration to an individual in need of treatment thereof.

23. Use of the composition of any one of claims 2, 10 or 11 in the manufacture of a medicament for the treatment of hyperactivity and/or attention deficit disorder in children.

24. A drug dosage dispenser comprising
   a composition for the oral administration of a drug to a patient comprising
   a first component in a form releasing a first dose of the drug immediately following ingestion of the composition; and
   a second component in a form rapidly releasing a second dose of the drug at a second time after release of the first dose,
   wherein the first and second doses provide a multi-spike pharmacokinetic profile of the drug and wherein the rapid release is achieved through the use of reagents that, upon exposure to water, generate a burst of gas reagents that immediately disperses or exposes the second dose of the drug so that it can be absorbed through the gastrointestinal tract.

25. The composition of claim 1 wherein the second component is in the form of pellets or microspheres comprising an acid and a dry powder, wherein the dry powder and acid, upon contact with water, will form and liberate carbon dioxide.

26. The composition of claim 5 wherein the acid is a food acid and the dry powder is baking powder.

27. The composition of claim 5 comprising a binding agent wherein the composition is in the form of a solid or semi-solid food or candy.

28. The composition of claim 1 in the form of a paste, jelly, suspension, or fast-dissolving wafer.

29. The composition of claim 1 in the form of a gelatinous solid.

30. The composition of claim 2 wherein the second dose is released after two to eight hours following release of the first dose.

31. The composition of claim 10 in the form of a paste or gel, capable of being administered using a compressible device for dispensing a measured dose of the composition.

32. The composition of claim 1 in the form of a solid or semi-solid which can be apportioned to provide the correct dosage form, and is suitable for being apportioned at the time of administration to an individual in need of treatment thereof.

33. Use of the composition of any one of claims 2, 10 or 11 in the manufacture of a medicament for the treatment of hyperactivity and/or attention deficit disorder in children.

34. A drug dosage dispenser comprising
   a composition for the oral administration of a drug to a patient comprising
   a first component in a form releasing a first dose of the drug immediately following ingestion of the composition; and
   a second component in a form rapidly releasing a second dose of the drug at a second time after release of the first dose,
   wherein the first and second doses provide a multi-spike pharmacokinetic profile of the drug and wherein the rapid release is achieved through the use of reagents that, upon exposure to water, generate a burst of gas reagents that immediately disperses or exposes the second dose of the drug so that it can be absorbed through the gastrointestinal tract.

35. The composition of claim 1 wherein the second component is in the form of pellets or microspheres comprising an acid and a dry powder, wherein the dry powder and acid, upon contact with water, will form and liberate carbon dioxide.

36. The composition of claim 5 wherein the acid is a food acid and the dry powder is baking powder.

37. The composition of claim 5 comprising a binding agent wherein the composition is in the form of a solid or semi-solid food or candy.

38. The composition of claim 1 in the form of a paste, jelly, suspension, or fast-dissolving wafer.

39. The composition of claim 1 in the form of a gelatinous solid.

40. The composition of claim 2 wherein the second dose is released after two to eight hours following release of the first dose.

41. The composition of claim 10 in the form of a paste or gel, capable of being administered using a compressible device for dispensing a measured dose of the composition.

42. The composition of claim 1 in the form of a solid or semi-solid which can be apportioned to provide the correct dosage form, and is suitable for being apportioned at the time of administration to an individual in need of treatment thereof.

43. Use of the composition of any one of claims 2, 10 or 11 in the manufacture of a medicament for the treatment of hyperactivity and/or attention deficit disorder in children.

44. A drug dosage dispenser comprising
   a composition for the oral administration of a drug to a patient comprising
   a first component in a form releasing a first dose of the drug immediately following ingestion of the composition; and
   a second component in a form rapidly releasing a second dose of the drug at a second time after release of the first dose,
   wherein the first and second doses provide a multi-spike pharmacokinetic profile of the drug and wherein the rapid release is achieved through the use of reagents that, upon exposure to water, generate a burst of gas reagents that immediately disperses or exposes the second dose of the drug so that it can be absorbed through the gastrointestinal tract.

45. The composition of claim 1 wherein the second component is in the form of pellets or microspheres comprising an acid and a dry powder, wherein the dry powder and acid, upon contact with water, will form and liberate carbon dioxide.

46. The composition of claim 5 wherein the acid is a food acid and the dry powder is baking powder.

47. The composition of claim 5 comprising a binding agent wherein the composition is in the form of a solid or semi-solid food or candy.

48. The composition of claim 1 in the form of a paste, jelly, suspension, or fast-dissolving wafer.

49. The composition of claim 1 in the form of a gelatinous solid.

50. The composition of claim 2 wherein the second dose is released after two to eight hours following release of the first dose.

51. The composition of claim 10 in the form of a paste or gel, capable of being administered using a compressible device for dispensing a measured dose of the composition.

52. The composition of claim 1 in the form of a solid or semi-solid which can be apportioned to provide the correct dosage form, and is suitable for being apportioned at the time of administration to an individual in need of treatment thereof.

53. Use of the composition of any one of claims 2, 10 or 11 in the manufacture of a medicament for the treatment of hyperactivity and/or attention deficit disorder in children.
a compressible device for dispensing a measured dose of the composition.

15. A drug dosage dispenser as claimed in claim 14, wherein the composition is a composition of any one of claims 1 to 12.

**Patentansprüche**

1. Eine Zusammensetzung zur oralen Verabreichung eines Arzneimittels an einen Patienten, umfassend eine erste Komponente in einer Form, die eine erste Dosis des Arzneimittels unmittelbar nach Einnahme der Zusammensetzung freisetzet; und eine zweite Komponente in einer Form, die eine zweite Dosis des Arzneimittels zu einem zweiten Zeitpunkt nach Freisetzung der ersten Dosis rasch freisetzet,

   wobei die erste und die zweite Dosis ein pharmakokinetisches Mehrfachspitzen-Profil des Arzneimittels liefern und wobei die rasche Freisetzung durch die Verwendung von Reagenzien erreicht wird, die bei Einwirkung von Wasser einen Burst von Gasreagenzien erzeugen, der die zweite Dosis des Arzneimittels unmittelbar dispergiert oder freisetzt, so dass sie durch den Gastrointestinaltrakt absorbiert werden kann.

2. Zusammensetzung nach Anspruch 1, wobei das Arzneimittel Methylphenidat ist.

3. Zusammensetzung nach Anspruch 1, die geschmacksmaskierende Materialien umfasst.

4. Zusammensetzung nach Anspruch 1, wobei das Arzneimittel der zweiten Komponente mit einem enterischen Überzug versehen ist und in feinteiliger Form nach Auflösen des enterischen Überzugs rasch freigesetzt wird.

5. Zusammensetzung nach Anspruch 1, wobei die zweite Komponente in Form von Pellets oder Mikrokugeln, die eine Säure und ein trockenes Pulver umfassen, wobei das trockene Pulver und die Säure bei Kontakt mit Wasser Kohlendioxid bilden und freisetzen, vorliegt.

6. Zusammensetzung nach Anspruch 5, wobei die Säure eine Nahrungsmittelsäure ist und das trockene Pulver Backpulver ist.

7. Zusammensetzung nach Anspruch 5, die ein Bindemittel umfasst, wobei die Zusammensetzung in Form eines festen oder halbfesten Nahrungsmittels oder einer festen oder halbfesten Süßigkeit vorliegt.

8. Zusammensetzung nach Anspruch 1 in Form einer Paste, eines Gelees, einer Suspension oder einer schnell auflösenden Oblate.

9. Zusammensetzung nach Anspruch 1 in Form eines gelatineartigen Feststoffs.

10. Zusammensetzung nach Anspruch 2, wobei die zweite Dosis nach zwei bis acht Stunden nach Freisetzung der ersten Dosis freigesetzt wird.

11. Zusammensetzung nach Anspruch 10 in Form einer Paste oder eines Gels, die in der Lage ist, unter Verwendung einer zusammendrückbaren Vorrichtung zum Verabreichen einer abgemessenen Dosis der Zusammensetzung verabreicht zu werden.

12. Zusammensetzung nach Anspruch 1 in Form eines Feststoffs oder Halbfeststoffs, der zugemessen werden kann, um die richtige Dosierform bereitzustellen, wobei die Zusammensetzung geeignet ist, zum Zeitpunkt der Verabreichung an ein Individuum, das einer Behandlung damit bedarf, zugemessen zu werden.


14. Arzneimitteldosierausgabevorrichtung, umfassend eine Zusammensetzung zur oralen Verabreichung eines Arzneimittels an einen Patienten, die die folgenden Bestandteile umfasst:

   - eine erste Komponente in einer Form, die eine erste Dosis des Arzneimittels unmittelbar nach Einnahme der Zusammensetzung freisetzt; und
   - eine zweite Komponente in einer Form, die eine zweite Dosis des Arzneimittels zu einem zweiten Zeitpunkt nach Freisetzung der ersten Dosis rasch freisetzt,

   wobei die erste und die zweite Dosis ein pharmakokinetisches Mehrfachspitzen-Profil des Arzneimittels liefern und wobei die rasche Freisetzung durch die Verwendung von Reagenzien erreicht wird, die bei Einwirkung von Wasser einen Burst von Gasreagenzien erzeugen, der die zweite Dosis des Arzneimittels unmittelbar dispergiert oder freisetzt, so dass sie durch den Gastrointestinaltrakt absorbiert werden kann; und

   - die Zusammensetzung in Form einer Paste oder eines Gels vorliegt, und

   - eine zusammendrückbare Vorrichtung zum Ausgeben einer abgemessenen Dosis der Zusammensetzung.
15. Arneimitteldosierausgabevorrichtung nach Anspruch 14, wobei die Zusammensetzung eine Zusammensetzung nach einem der Ansprüche 1 bis 12 ist.

Revendications

1. Composition pour l’administration orale d’un médicament à un patient, comprenant un premier composant sous une forme libérant une première dose du médicament immédiatement après l’ingestion de la composition ; et un second composant sous une forme libérant rapidement une seconde dose du médicament à un second moment après la libération de la première dose,
dans laquelle les première et seconde doses fournissent un profil pharmacocinétique à pics multiples du médicament et dans laquelle la libération rapide est obtenue par l’utilisation de réactifs qui, sous l’effet d’une exposition à l’eau, génèrent une explosion de réactifs gazeux qui disperse ou explose immédiatement la seconde dose du médicament de telle sorte qu’elle peut être absorbée par le tractus gastro-intestinal.

2. Composition selon la revendication 1, dans laquelle le médicament est le méthylphénidate.

3. Composition selon la revendication 1 comprenant des substances de masquage du goût.

4. Composition selon la revendication 1, dans laquelle le médicament du second composant est gastrorésistant et est rapidement libéré sous une forme finement divisée après la dissolution de l’enrobage gastrorésistant.

5. Composition selon la revendication 1, dans laquelle le second composant se trouve sous la forme de pastilles ou de microsphères comprenant un acide et une poudre sèche, dans laquelle la poudre sèche et l’acide, sous l’effet d’un contact avec l’eau, se formeront et libéreront du dioxyde de carbone.

6. Composition selon la revendication 5, dans laquelle l’acide est un acide alimentaire et la poudre sèche est de la levure chimique.

7. Composition selon la revendication 5 comprenant un agent liant, dans laquelle la composition se trouve sous la forme d’un aliment ou d’un bonbon solide ou semi-solide.

8. Composition selon la revendication 1 sous la forme d’une pâte, d’une gelée, d’une suspension, ou d’un cachet à dissolution rapide.

9. Composition selon la revendication 1 sous la forme d’un solide gélatineux.

10. Composition selon la revendication 2, dans laquelle la seconde dose est libérée 2 à 8 heures après la libération de la première dose.

11. Composition selon la revendication 10 sous la forme d’une pâte ou d’un gel, pouvant être administrée en utilisant un dispositif compressible de distribution d’une dose mesurée de la composition.

12. Composition selon la revendication 1 sous la forme d’un solide ou d’un semi-solide qui peut être partagée pour fournir la forme posologique correcte, et qui est adaptée à être partagée au moment de l’administration à un individu nécessitant un traitement avec celle-ci.


14. Distributeur de doses de médicament comprenant une composition pour l’administration orale d’un médicament à un patient, comprenant un premier composant sous une forme libérant une première dose du médicament immédiatement après l’ingestion de la composition ; et un second composant sous une forme libérant rapidement une seconde dose du médicament à un second moment après la libération de la première dose,
dans laquelle les première et seconde doses fournissent un profil pharmacocinétique à pics multiples du médicament et dans laquelle la libération rapide est obtenue par l’utilisation de réactifs qui, sous l’effet d’une exposition à l’eau, génèrent une explosion de réactifs gazeux qui disperse ou explose immédiatement la seconde dose du médicament de telle sorte qu’elle peut être absorbée par le tractus gastro-intestinal,
dans lequel la composition se trouve sous la forme d’une pâte ou d’un gel, et un dispositif compressible de distribution d’une dose mesurée de la composition.

15. Distributeur de doses de médicament tel que revendiqué dans la revendication 14, dans lequel la composition est une composition selon l’une quelconque des revendications 1 à 12.